Brickell Biotech Inc

NASDAQ:BBI  
0.94
+0.05 (+5.07%)
Products, Regulatory

Brickell Biotech Completes Patient Enrollment In Phase 3 Study Of Sofpironium Bromide Gel To Treat Primary Axillary Hyperhidrosis

Published: 04/27/2021 11:42 GMT
Brickell Biotech Inc (BBI) - Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis.
Brickell Biotech Inc - Phase 3 Pivotal Cardigan Ii Study Exceeds 50% Enrollment.
Brickell Biotech Inc - Topline Results for Phase 3 Pivotal Cardigan I and Cardigan Ii Clinical Studies Expected in Q4 2021.